Press Room

2021 Online Booth

Start
Thursday, September 30, 2021 - 00:00
End
Saturday, October 30, 2021 - 00:00
Location: online
Hovione Virtual Stand 2021 Online Booth | Hovione

Meet our experts at the pharma industry-leading events

 

We attend the leading events of the pharma industry throughout the year to present our Services & Products, sharing our scientists' innovative work.



Count on our multidisciplinary teams to understand, develop and improve your project. As a specialist integrated CDMO we are dedicated to helping you bring new and off-patent drugs to market faster.



Schedule an in-person meeting or virtual conversation beforehand and find out how we can support your project.

 

 

Hovione at a Glance | Hovione

Get to know more about our history

e-Brochures | Hovione

Explore what we do

Integrated CDMO | Hovione

Webinars, Articles & More

Cork Site | Hovione

We welcome you to our sites

Events | Hovione

Events will be attending

Analytical Development | Hovione

Our experts will help you

 

 

SOLVING YOUR CHALLENGES

Read the article from C&EN "One molecule’s journey from discovery to market" to find out how Hovione helped one customer solve their problem and succeed. More case studies will be available soon.

 

 

Subscribe to our newsletter and be the first to know.

 

 

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026